$AGEN today:1. Potential $$ from partners (INCY,$MRK,$GSK) up to $510M, $100M, $40M, respectively 2. Potential sources sustainable revenue (PD1, CTLA-4) potential BLA محمد الشهري . 3. First/best-in-class agents: only company w in-house CPMs, cellTx, adjuvants, BiS, neoantigen vaccines

What it takes to deliver INDs at a prolific rate and industry-leading speed? Learn how $AGEN achieved this by bringing cell-line development and GMP manufacturing, in-house. #Immunotherapy #innovation Agenus

Thank you Chairman Burr, Vice Chairman Warner, and the committee, for the opportunity to speak on behalf of Twitter to the American people. I look forward to our conversation about the work we’re doing to help protect the integrity of US elections, and elections around the world.

Heart rate during a Senate and House hearing

Received $15 M from $XOMA for minority royalty interest in $INCY, $MRK partnerships. $AGEN retain 67% of royalties and 90% of milestone payments; Remain eligible for up to an additional $450 M and $85.5 M in milestones from Incyte and Merck, respectively bit.ly/2Nyb5Kw

Today’s announcement is the first and the smallest of multiple transactions we expect to conclude this year. Agenus Closes $15 Million Partial Royalty Monetization With XOMA investor.agenusbio.com/2018-09-21-Age…

There will also be unscrupulous characters who intentionally say wrong or do wrong regardless of the facts.

Newsletter, Issue 6, focuses on our partnerships: -QS-21 enable $GSK vaccines including Shingrix® -Partnership w/ $MRK delivered First-In-Class Antibody to the Clinic -Enabled $INCY I-O portfolio w/ 4 clinical stage #Antibodies -Future partnerships. Read: bit.ly/2O4maSR

New data on lead programs at #ESMO18 including: - Proprietary #CTLA4 (AGEN1884) & #PD1 (AGEN2034) combination in advanced/refractory solid #tumors, including 2L #CervicalCancer - PD-1 dose escalation and expansion in 2L cervical cancer. #immunotherapy bit.ly/2RCwmAT

$AGEN hits 2018 milestones w AGEN1181 (nex-gen CTLA-4) FDA safe to proceed to clinic + IND filed for AGEN1223 (first-in-class intratumoral Treg depleting Bispecific). So far, 5 INDs in 2018 & one more on its way (AGEN1423). #immunoOncology #patientcare

.Gilead Sciences and Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies agenusbio.com/#.XBuOYnd5c3w.…

Y’all remember what life was like before Cascade dishwasher pods?

“This feels like 1999 again.” No, it doesn’t. And I was there (here). I joined Cisco in January 2000 as a co-op, then full-time in May 2001. At the time, Cisco was the hottest infra company on the planet, riding the wave of the dot-com boom. But by the time I started